Journal of Peking University(Health Sciences) >
Detection of preoperative chemoradiotherapy sensitivity molecular characteristics of rectal cancer by transcriptome second generation sequencing
Received date: 2019-03-25
Online published: 2019-06-26
Supported by
Supported by the Fundamental Research Funds for the Central Universities: Peking University Clinical Medicine Plus X-Young Scholars Project (PKU2018LCXQ021)
Wei ZHANG , Ying-jiang YE , Xian-wen REN , Jing HUANG , Zhan-long SHEN . Detection of preoperative chemoradiotherapy sensitivity molecular characteristics of rectal cancer by transcriptome second generation sequencing[J]. Journal of Peking University(Health Sciences), 2019 , 51(3) : 542 -547 . DOI: 10.19723/j.issn.1671-167X.2019.03.025
| [1] | Park IJ, You YN, Agarwal A , et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer[J]. J Clin Oncol, 2012,30(15):1770-1776. |
| [2] | Dworak O, Keilholz L, Hoffmann A . Pathological features of rectal cancer after preoperative radiochemotherapy[J]. Int J Colorectal Dis, 1997,12(1):19-23. |
| [3] | R?del C, Martus P, Papadoupolos T , et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer[J]. J Clin Oncol, 2005,23(34):8688-8696. |
| [4] | Fokas E, Liersch T, Fietkau R , et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial[J]. J Clin Oncol, 2014,32(15):1554-1562. |
| [5] | Smith JD, Ruby JA, Goodman KA , et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy[J]. Ann Surg, 2012,256(6):965-972. |
| [6] | Postmus I, Trompet S, Deshmukh HA , et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL choleste-rol response to statins[J]. Nat Commun, 2014,5:5068. |
| [7] | Williamson JS, Jones HG, Williams N , et al. Extramural vascular invasion and response to neoadjuvant chemoradiotherapy in rectal cancer: influence of the CpG island methylator phenotype[J]. World J Gastrointest Oncol, 2017,9(5):209-217. |
| [8] | Chand M, Swift RI, Tekkis PP , et al. Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer[J]. Br J Cancer, 2014,110(1):19-25. |
| [9] | Birlik B, Obuz F, Elibol FD , et al. Diffusion-weighted MRI and MR-volumetry: in the evaluation of tumor response after preoperative chemoradiotherapy in patients with locally advanced rectal cancer[J]. Magn Reson Imaging, 2015,33(2):201-212. |
| [10] | McCawley N, Clancy C, O’Neill BD , et al. Mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: A systematic review and meta-analysis[J]. Dis Colon Rectum, 2016,59(12):1200-1208. |
| [11] | Agarwal A, Chang GJ, Hu CY , et al. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy[J]. Cancer, 2013,119(24):4231-4241. |
| [12] | Maas M, Nelemans PJ, Valentini V , et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data[J]. Lancet Oncol, 2010,11(9):835-844. |
| [13] | Gérard JP, Chamorey E, Gourgou-Bourgade S , et al. Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial[J]. Radiother Oncol, 2015,115(2):246-252. |
| [14] | Chen MB, Wu XY, Yu R , et al. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer[J]. PLoS One, 2012,7(9):e45388. |
| [15] | D’Angelo E, Zanon C, Sensi F , et al. miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma[J]. J Clin Pathol, 2018,71(4):344-350. |
| [16] | Agostini M, Zangrando A, Pastrello C , et al. A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients[J]. Cancer Biol Ther, 2015,16(8):1160-1171. |
| [17] | Scott JG, Berglund A, Schell MJ , et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study[J]. Lancet Oncol, 2016,18(2):202-211. |
| [18] | Regine WF, Winter KA, Abrams RA , et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial[J]. JAMA, 2008,299(9):1019-1026. |
| [19] | Coveler AL, Richard P, Apisarnthanarax S , et al. Is there a best radiosensitizing agent in the treatment of locally advanced rectal cancer?[J]. Current Colorectal Cancer Reports, 2016,12(4):189-200. |
| [20] | Aschele C, Cionini L, Lonardi S , et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the star-01 rando-mized phase Ⅲ trial[J]. J Clin Oncol, 2011,29(20):2773-2780. |
/
| 〈 |
|
〉 |